These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10994654)

  • 1. Second International Pharmacoeconomic Conference on Alzheimer' s Disease.
    Jönsson L; Jönsson B; Wimo A; Whitehouse P; Winblad B
    Alzheimer Dis Assoc Disord; 2000; 14(3):137-40. PubMed ID: 10994654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary.
    Whitehouse PJ; Winblad B; Shostak D; Bhattacharjya A; Brod M; Brodaty H; Dor A; Feldman H; Forette F; Gauthier S; Hay J; Henke C; Hill S; Mastey V; Neumann P; O'Brien B; Pugner K; Sano M; Sawada T; Stone R; Wimo A
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):266-80. PubMed ID: 9876955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics of dementia.
    Whitehouse PJ
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 5():S22-32; discussion S32-3. PubMed ID: 9348424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economics of dementia and pharmacoeconomics of dementia therapy.
    Fillit H; Hill J
    Am J Geriatr Pharmacother; 2005 Mar; 3(1):39-49. PubMed ID: 16089246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease.
    Bergvall N; Brinck P; Eek D; Gustavsson A; Wimo A; Winblad B; Jönsson L
    Int Psychogeriatr; 2011 Feb; 23(1):73-85. PubMed ID: 20619068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.
    Getsios D; Blume S; Ishak KJ; Maclaine G; Hernández L
    Alzheimers Dement; 2012 Jan; 8(1):22-30. PubMed ID: 21420366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.
    Garfield FB; Getsios D; Caro JJ; Wimo A; Winblad B
    Pharmacoeconomics; 2002; 20(9):629-37. PubMed ID: 12141890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia.
    Katona C; Livingston G; Cooper C; Ames D; Brodaty H; Chiu E
    Int Psychogeriatr; 2007 Jun; 19(3):345-54. PubMed ID: 17386120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donepezil. Pharmacoeconomic implications of therapy.
    Foster RH; Plosker GL
    Pharmacoeconomics; 1999 Jul; 16(1):99-114. PubMed ID: 10539126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IPECAD5--Fifth International Pharmaco-Economic Conference on Alzheimer's Disease.
    Gustavsson A; Jonsson L; Fillit H; Johansson G; Wimo A; Winblad B
    J Nutr Health Aging; 2010 May; 14(5):358-60. PubMed ID: 20424802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the costs of informal care for people with Alzheimer's disease: methodological and practical challenges.
    McDaid D
    Int J Geriatr Psychiatry; 2001 Apr; 16(4):400-5. PubMed ID: 11333428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relief for caregivers. Anti-dementia drug saves costs].
    MMW Fortschr Med; 2001 Oct; 143(42):64. PubMed ID: 11697297
    [No Abstract]   [Full Text] [Related]  

  • 14. Where are we at with model-based economic evaluations of interventions for dementia? a systematic review and quality assessment.
    Nguyen KH; Comans TA; Green C
    Int Psychogeriatr; 2018 Nov; 30(11):1593-1605. PubMed ID: 30475198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany.
    Guo S; Hernandez L; Wasiak R; Gaudig M
    J Med Econ; 2010; 13(4):641-54. PubMed ID: 20958114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of costs of care for patients with Alzheimer's disease.
    Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
    Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dependence Stage and Pharmacoeconomic Outcomes in Patients With Alzheimer Disease.
    Michaud TL; High R; Charlton ME; Murman DL
    Alzheimer Dis Assoc Disord; 2017; 31(3):209-217. PubMed ID: 28486240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment.
    Wimo A; Winblad B; Grafstrom M
    Int J Geriatr Psychiatry; 1999 May; 14(5):338-47. PubMed ID: 10389036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing health economic outcome in Alzheimer's disease clinical trials.
    Jonsson L
    J Nutr Health Aging; 2007; 11(4):353-5. PubMed ID: 17653498
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.